SG Americas Securities LLC Buys New Stake in Celldex Therapeutics, Inc. $CLDX

SG Americas Securities LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,468 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Several other institutional investors and hedge funds also recently modified their holdings of CLDX. Commodore Capital LP increased its holdings in shares of Celldex Therapeutics by 7.8% during the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after purchasing an additional 250,000 shares during the period. Bellevue Group AG increased its stake in Celldex Therapeutics by 7.7% during the 2nd quarter. Bellevue Group AG now owns 3,307,569 shares of the biopharmaceutical company’s stock valued at $67,309,000 after buying an additional 235,954 shares during the period. Vestal Point Capital LP increased its stake in Celldex Therapeutics by 781.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $35,612,000 after buying an additional 1,551,354 shares during the period. Geode Capital Management LLC raised its position in shares of Celldex Therapeutics by 5.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock worth $34,050,000 after buying an additional 83,174 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Celldex Therapeutics by 24.7% in the 2nd quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock worth $15,873,000 after acquiring an additional 154,664 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CLDX. Barclays raised their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. Mizuho assumed coverage on Celldex Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.10.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $25.92 on Friday. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $30.50. The business’s fifty day moving average is $26.67 and its two-hundred day moving average is $25.04. The stock has a market capitalization of $1.72 billion, a P/E ratio of -7.67 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. On average, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Insiders Place Their Bets

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the sale, the insider owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.